1. Main
  2. Learn
  3. Industry
  4. Science, Technologies

Breast cancer gene patents reach US high court 16 апреля 2013, 14:41

Breast cancer gene patents reach US high court Breast cancer gene patents reach US high court
The US Supreme Court heard the most high-profile genetics case in history on Monday, as justices considered whether private firms should be allowed to patent human genes linked to breast cancer, AFP reports. The court's decision could have broad implications for research, patient health and the pharmaceutical industry, with nearly 20 percent of the approximately 24,000 human genes currently under patent, some linked to cancer and Alzheimer's disease. At issue are the actions of Myriad Genetics, a Utah-based company which holds patents on genes known as BRCA1 and BRCA2, both associated with hereditary breast and ovarian cancer. The firm says patents for the two genes, awarded in 1998, have helped it raise the money "necessary to decode the genes, design and deliver the tests, interpret the results, and help patients," to the benefit of a million people. Critics accuse Myriad of barring research by other institutions on the BRCA genes and making the test too expensive for many patients, with a cost of $3,000 to $4,000. Inside the court, Justice Elena Kagan asked if a plant in the Amazon could be patented because it was hard to find, and Justice Sonia Sotomayor likened the matter to patenting elements of a favorite recipe. "I create my chocolate cookies, I can get a patent on that but I cannot imagine a patent for salt, flour and eggs," Sotomayor said. Dozens of breast cancer survivors and women's health advocates assembled on the Supreme Court steps as the arguments were heard inside. Some hoisted signs, including one that read: "Corporate Greed is Killing My Friends." One of the plaintiffs, Lisbeth Ceriani, said her doctors recommended the test after she was diagnosed with breast cancer, but she was initially unable to get it because Myriad did not contract with her health insurance to cover the cost. She later found the means to pay for it with the help of a grant. "It's important to me because there are so many other women who have not been able to access the test. I have a daughter who will one day need to be tested," she said outside the court. "Competition is what leads to innovation and improvement," said Harry Ostrer, a medical geneticist and another plaintiff in the case. If Myriad did not own the patents, "I would start offering testing to my poor patients in the Bronx," he added. Opponents of gene patenting in this case, led by the American Civil Liberties Union, include more than 150,000 geneticists, pathologists and laboratory professionals. The ACLU argued that patents on human genes "violate the First Amendment and patent law because genes are 'products of nature' and therefore can't be patented." Countering that point, Myriad attorney Gregory Castanias told the nine justices that "genes are themselves a human construction." James Watson, Nobel laureate and co-discoverer, with the late Francis Crick, of DNA's double helix structure in 1953, filed an amicus brief that argued human genes are a product of nature and cannot be monopolized by any entity. "Knowledge per se cannot be patented. Myriad should not own breast cancer genes," Watson said outside the Supreme Court. In February, an Australian court ruled against the plaintiffs in a similar case, rejecting the argument that BRCA1 could not be patented because it was a naturally occurring substance and finding in favor of Myriad Genetics and Melbourne-based Genetic Technologies Ltd. A decision by the US Supreme Court is expected in June. Scott Elmer, director, Office of Technology Licensing at St. Jude Children's Research Hospital, said he wanted the court to establish what can and cannot be the subject of a patent. "This clarity will help everyone focus on using the patent system in an appropriate way to promote the progress of science," he said.

Nobel prizewinner proposes a new city in KZ
New abnormal snowfalls expected in Kazakhstan
Huge glacier retreat triggered in 1940s
Hyperloop construction begins in Las Vegas
"Moonlight" to top Spirit Awards nominations
Oil prices fall due to investors uncertainty
New dwarf galaxy discovered around Milky Way
Kanat Islam becomes a top ten WBO boxer
World oil prices continue to rise
Kazakhstan expects warming - Kazhydromet
Merkel to seek fourth term as chancellor
Sale of Tintin drawings set to break records
US, EU stocks fall as markets focus on dollar
Pacific leaders urged to defend free trade
EU warns eight nations on budget deficit
Universiade-2017: Athletic Village is ready
Bob Dylan can't make Nobel ceremony
Messi will never leave Barca - club president
Google, Facebook take aim at 'fake' news
Aerosmith announces Europe 'farewell' tour
Putin, Trump to normalise US-Russia ties
At least 10 hurt in southern Turkey blast
6.2 quake hits western Japan
OPEC agrees shock oil output cut
Israeli ex-president and Nobel laureate Peres dies
Germany blocks WhatsApp data transfers to Facebook
32,000 arrested in Turkey coup probe
Youth to the fore as Milan fashion week opens
Xenophobia threatening peace in eastern Germany
Four-in-10 Japanese are virgins: poll
Sweden re-militarises Baltic island of Gotland
China to launch second space laboratory: Xinhua
More than a billion stars mapped in Milky Way: ESA
Boxing: Golovkin eyes Saunders after stopping Brook
Kazakhstan shifts PM to security chief
Oil prices gain despite rising OPEC supply forecast
US to give Philippines military planes
Singapore wages war on Zika-bearing mosquitoes
Italy quake death toll nears 250
Viral photos add fuel to French burkini debate
18 dead as Italy struck by powerful quake
Japan's first lady visits Pearl Harbor
Pokemon's a no-go on Bangkok's roads
July was Earth's hottest month in modern times
Pakistan rock climbers scale new heights